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a b s t r a c t
Bronchiolitis obliterans syndrome (BOS) is a signiﬁcant post-transplant complication with low survival. BOS
stage 0p (BOS 0p) is a parameter detected on pulmonary function tests (PFTs) after lung transplantation to
identify patients at risk to develop BOS. We performed a retrospective study on 442 patients who underwent
allogeneic stem cell transplant from 2007 to 2011 to evaluate whether development of BOS 0p is a risk factor
in this population for BOS. Patients who met criteria for BOS 0p were signiﬁcantly more likely to develop BOS
(hazard ratio [HR], 3.22; P < .001). BOS 0p was signiﬁcantly associated with a history of lung disease pre-
transplant (HR, 2.48; P ¼ .001) and chronic graft-versus-host disease (GVHD) outside the lung post-transplant
(HR, 23; P < .001). Finally, BOS 0p criteria were adequately sensitive in predicting BOS (85%), with a high
negative predictive value (98%). Our ﬁndings suggest a routine PFT screening strategy with the intent of
detecting BOS 0p, especially among patients with prior lung disease and who developed chronic GVHD, could
suitably identify an at-risk population for the development of BOS.
 2015 American Society for Blood and Marrow Transplantation.
INTRODUCTION
Chronic graft-versus-host disease (GVHD) of the lung
manifests as bronchiolitis obliterans syndrome (BOS), one of
the most serious pulmonary complications after allogeneic
hematopoietic stem cell transplantation (HSCT). Pathologi-
cally, BOS is characterized by progressive ﬁbroproliferation
within the terminal bronchioles in the lungs, resulting in
obliteration of airway lumens [1]. Clinically, BOS appears as
ﬁxed airﬂow obstruction on spirometry, and at the time of
diagnosis most patients present with moderate to severe dis-
ease [1,2]. After diagnosis, BOS typically follows an irreversible
and progressive decline in lung function despite therapeutic
intervention, with 5-year survival rates as low as 13% [1-3].
In this setting, anticipating irreversible lung damage from
BOS is an essential strategy to improve outcomes through
earlier preventive or therapeutic interventions. Previous
studies have shown that patients who experience an
annualized decrease in forced expiratory volume in 1 second
(FEV1) by 5% or more at 1-year after allogeneic HSCT are at an
increased mortality risk, particularly among patients with
chronic GVHD [4]. Presumably, detecting early airﬂow
obstruction may identify patients at risk of death due to BOS,
among other causes.
BOS stage 0p (BOS 0p) is a spirometric parameter applied
to identify patients with the potential to develop BOS after
lung transplantation where it also represents a signiﬁcant
complication, with clinical and pathologic similarities to
chronic GVHD of the lung [5]. BOS 0p is met when a decline
in FEV1 of 10% to 19% of predicted normal or a decline in
predicted forced expiratory ﬂow between 25% and 75% of
vital capacity (FEF25-75) > 25% is observed on consecutive
pulmonary function tests (PFTs); in lung transplantation
patients it can predict the development of BOS [5-7]. In this
single-institution study, we evaluated BOS 0p as a predictor
for BOS in a cohort of allogeneic transplant patients.
METHODS
We retrospectively evaluated all patients age 18 years and older who
underwent allogeneic HSCT at the University of Michigan Blood andMarrow
Transplantation Program between January 1, 2007 and December 31, 2011.
Four hundred forty-two consecutive patients were identiﬁed, and we
reviewed their outcomes through December 31, 2013. Transplants beyond
the ﬁrst 1 were excluded from the study. Data were obtained from the
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University of Michigan Blood and Marrow Transplantation database. This
study was performed under institutional review board approval at the
University of Michigan Health System.
The diagnosis of BOS was determined using clinical criteria established
by the chronic GVHD Working Group at the National Institutes of Health
requiring the following: (1) FEV1/forced vital capacity ratio <.7 and FEV1
<75% of predicted, (2) evidence of airway obstruction on high-resolution
computed tomography or a residual volume on PFTs >120%, (3) absence of
infection in the respiratory tract, and (4) histologic diagnosis of BOS or at
least 1 other manifestation of chronic GVHD in an additional organ system
[8]. Infectionwas assessed in patients by clinical examination, microbiologic
assessment, and radiologic assessment with either chest radiograph or
computed tomography of the chest. The date of detection of BOS was noted
as the date of the PFT performed that met criteria for BOS.
BOS 0p was determined using similar criteria applied to lung trans-
plantation patients. Thus, the diagnostic criteria for BOS 0p were as follows:
(1) a decline of 10% predicted FEV1 or (2) a decline of 25% predicted
FEF25-75 but (3) not otherwise meeting criteria for BOS. These ﬁndings had to
be present in at least 2 consecutive PFTs. The date of detection of BOS 0p was
noted as the date of the ﬁrst PFT that demonstrated BOS 0p. PFTs were
examined from pretransplant through last date of follow-up, death, or
relapse, whichever occurred ﬁrst.
All spirometry was performed according to American Thoracic Society
guidelines. The University of Michigan Health Systemepredicted equations
for adults are derived from a combination of sources of data in the literature
established approximately 15 years ago. For our study, we recorded forced
vital capacity, vital capacity, FEV1, and FEF25-75, all computed according to
the equations ofMorris et al. [9]. Per institutional guidelines, spirometrywas
obtained pretransplant, deﬁned as spirometry performed within 1 month of
transplant, at day 100, at day 180, and at 1 year. After 1 year, measurement
interval varied based on transplantation physician preference and patients’
clinical states. In most cases, the interval between PFTs was 3 months, and
the largest interval between PFTs was 6 months. After 2 years, patients with
chronic GVHD continued to have spirometry performed annually at a min-
imum. Patients without chronic GVHD underwent spirometry at the
discretion of the primary transplant physician.
Clinical data analyzed in this study were collected prospectively in a
database for long-term transplant follow-up. Pretransplant characteristics
collected included age, gender, stem cell source, conditioning regimen, and
tobacco use history. Additionally, we identiﬁed whether a patient had a
history of lung disease before transplant. Pulmonary conditions included in
this history were a history of chronic obstructive pulmonary disease,
asthma, pulmonary embolism, or persistent pleural effusion. Finally, diag-
nosis and staging of acute and chronic GVHD were collected, with deter-
mination and staging assigned using previously established criteria [8,10].
A competing risks regression model according to the methods of Fine
and Gray [11] and Gray [12] were used to assess the association of patient
characteristics with BOS and BOS 0p, treating death and relapse as
competing risks. Cox regression without competing risks was used to assess
the association of acute and chronic GVHD with BOS and BOS 0p, treating
acute and chronic GVHD as time-varying covariates. Cox regression without
competing risks was used to assess the association of BOS and BOS 0p with
overall survival, treating BOS and BOS 0p as time-varying covariates.
Sensitivity, speciﬁcity, and predictive values of BOS 0p, FEV1 criterion,
and FEF25-75 criterion to detect BOS were calculated. Patients included in
these analyses had a minimum 180 days of follow-up. Additionally, we only
included patients who developed BOS 0p within 2 years. Finally, upon
development of BOS 0p, we included patients with a minimum 1-year
follow-up after detection of BOS 0p. All analyses were done in the statisti-
cal package R (R Development Core Team, Vienna, Austria).
RESULTS
Patient Characteristics
Four hundred forty-two patients ages 18 years and older
underwent allogeneic HSCT between 2007 and 2011; base-
line patient characteristics are outlined in Table 1. Most pa-
tients weremen (n¼ 259, 59%) with amedian age of 54 years
(range, 18 to 73 years). Most patients underwent myeloa-
blative conditioning before transplant (n ¼ 301, 68%), and
most patients had a matched-sibling allogeneic SCT. Stem
cell source in nearly all patients was peripheral blood (n ¼
403, 91%). At the end of our follow-up interval, 175 patients
were alive, with a median follow-up of 3.95 years (range,
2.01 to 6.96 years).
All patients in this study had pretransplant spirometry.
Eighty-two patients (19%) underwent spirometry once, with
relapse or death limiting additional tests. Remaining patients
underwent a median of 6 PFT studies (range, 2 to 28), and, in
total, of 2358 PFTs were performed on all patients.
Diagnosis and Risk Factors for BOS
Twenty-six patients developed BOS by the end of our
follow-up interval. The cumulative incidence of BOS was 5%
(95% conﬁdence interval, 3% to 6%) at 2 years post-transplant
(Figure 1A). Median time to detection of BOS was 401 days
(range, 178 to 1218). Upon detection of BOS, median percent-
predicted FEV1 was 52% (range, 25% to 75%), indicating
moderate to severe airﬂow obstruction, andmedian percent-
predicted FEF25-75 was 21% (range, 8% to 42%). Finally,
development of BOS was signiﬁcantly associated with
increased mortality by the end of the study period (hazard
ratio [HR], 1.92; P ¼ .035).
Multivariate analysis of pretransplant characteristics
revealed that only a history of lung disease was associated
with development of BOS. Patients with history of lung dis-
ease pretransplant were 4 times more likely to develop BOS
compared with patients without lung disease (HR, 4.05; P ¼
.001). In our study, stem cell source, total body irradiation,
myeloablative conditioning, prior tobacco use, or history of
Table 1
Patient Characteristics
Clinical Characteristics Value
Median age, yr (range) 54 (18-73)
Sex
Male 259 (59%)
Female 183 (41%)
Disease risk
Low 147 (33%)
Intermediates 121 (28%)
High 174 (39%)
Donor type
Sibling 224 (51%)
Unrelated 218 (49%)
HLA status
Matched 345 (78%)
Mismatched 78 (18%)
Stem cell source
Peripheral blood 403 (91%)
Bone marrow 23 (5%)
Cord blood 16 (4%)
Conditioning intensity
Myeloablative 301 (68%)
Reduced intensity 141 (32%)
Conditioning regimen
Myeloablative, busulfan 216 (49%)
TBI 65 (15%)
Acute GVHD
Grades I-IV 277 (63%)
Grades III-IV 87 (20%)
Chronic GVHD
Mild 67 (15%)
Moderate 87 (20%)
Severe 60 (14%)
Baseline lung function
FEV1, mean (range) 97 (39-144)
FEF25-75, mean (range) 83 (12-165)
Previous tobacco use
Yes 189 (43%)
No 253 (57%)
Prior lung disease
Yes 46 (10%)
No 396 (90%)
TBI indicates total body irradiation.
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grades III-IV acute GVHD post-transplant were not associated
with the development of BOS (Table 2) [13-16].
Post-transplant, patients who met criteria for BOS
0p were signiﬁcantly more likely to develop BOS (HR, 3.22;
P < .001). Detection of BOS 0p preceded BOS in 22 patients
(85%). In these patients, BOS 0pwas detected within 1 year in
19 patients (86%) and between 1 and 2 years in 3 patients
(14%). Further, criteria for BOS 0p were met at a median of
222 days (range, 21-1039) before BOS. Progression from BOS
0p to BOS on spirometry occurred within 3 months in 4
patients, within 3 and 6 months in 4 patients, within 6 and 9
months in 9 patients, and over 1 year in 5 patients.
Four remaining patients (15%) developed BOS without
ﬁrst meeting criteria for BOS 0p because of a signiﬁcant
decline in lung function between consecutive measurements
of lung function that met criteria for BOS. These 4 patients
developed BOS within 1 year.
Diagnosis and Risk Factors for BOS 0p
Seventy-nine patients met criteria for BOS 0p, with an
estimated 2-year cumulative incidence of 16% (95% conﬁ-
dence interval, 13% to 20%) (Figure 1B). The median time to
detection of BOS 0p was 273 days (range, 32 to 1910 days).
Detection of BOS 0p occurred within 1 year in 51 patients
(65%), within 1 and 2 years in 22 patients (28%), and after 2
years in 6 patients (7%). The median percent-predicted FEV1
on development of BOS 0p was 81% (range, 30% to 114%), and
the median percent-predicted FEF25-75 was 65% (range, 11%
to 128%).
In most patients, we detected signiﬁcant changes to the
percent-predicted FEV1 at the time of diagnosis of BOS 0p. At
diagnosis of BOS 0p, 39 patients (49%) had both>10% decline
to the percent-predicted FEV1 and >25% decline to FEF25-75;
31 patients (39%) had >10% decline in their percent-
predicted FEV1 only, and 9 of these patients (12%) experi-
enced a >25% decline in their percent-predicted FEF25-75
only (Figure 2). The development of BOS 0p was not associ-
ated with a higher mortality rate.
As in the case with BOS, multivariate analysis revealed
that BOS 0p was signiﬁcantly associated with a history of
lung disease pretransplant (HR, 2.48; P ¼ .001). Sixteen pa-
tients (20%) with BOS 0p had a pretransplant history of lung
disease. Eight of these patients (50%) progressed to BOS. Age,
sex, conditioning regimen, or cell source were not associated
with BOS 0p. Analysis of time-varying characteristics
revealed that development of grades III to IV acute GVHD and
chronic GVHD outside the lung were strongly associated
with the development of BOS 0p (HR, 1.85; P ¼ .038 and HR,
23; P < .001, respectively) (Table 3). Seventy-two patients
(91%) with BOS 0p had a history of chronic GVHD. None of
the patients who met criteria for BOS 0p without chronic
GVHD later met spirometric criteria for BOS.
Predictive Characteristics of BOS 0p
The performance of the FEV1 criterion, FEF25-75 criterion,
and BOS 0p criteria as predictors of BOS are outlined in
Table 4. Two hundred seventy-ﬁve patients were included
for these analyses. BOS 0p criteria overall had the best
Figure 1. Cumulative incidence of (A) BOS and (B) BOS 0p.
Table 2
Associations with BOS
Risk Factor HR P
Age .99 .69
Sex
Male 1.00 (ref) .61
Female 1.21
Stem cell source
Bone marrow 1.00 (ref) .87
Peripheral blood 1.14
Myeloablative, busulfan 1.43 .38
TBI .48 .3
Previous tobacco use .98 .97
Previous lung disease 4.05 .001
Grades III-IV acute GVHD 1.93 .14 Figure 2. Venn diagram illustrating the PFT change responsible for detection
of BOS 0p.
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performance characteristics. Our results indicated that the
false-positive rate for the BOS 0p criteria was high, reﬂected
by a low positive predictive value (29%) and fair speciﬁcity
(78%). However, the overall sensitivity for the detection of
BOS by the BOS 0p criteria was good (85%). Furthermore, the
BOS 0p criteria had a very good negative predictive value
(98%). The FEV1 criterion had comparable performance
characteristics with similar sensitivity (77%) and a similar
negative predictive value (97%). The false-positive rate was
essentially no different from the BOS 0p criteria (positive
predictive value ¼ 30%, speciﬁcity ¼ 81%). The FEF25-75 cri-
terion demonstrated a marginally lower false-positive rate,
reﬂected by a higher speciﬁcity (88%) and higher positive
predictive value (37%), but at the expense of sensitivity (65%).
DISCUSSION
BOS represents a rare but signiﬁcant post-transplant
complication, with very low survival rates after diagnosis
[2]. The syndrome is usually diagnosed at a relatively
advanced stage, where the higher likelihood of irreversible
lung damage limits the efﬁcacy of available therapies and
survival [2,3]. So far, lung transplantation is the only curative
treatment of severe BOS after allogeneic HSCT, where the
primary disease process leading to allogeneic transplant was
otherwise controlled [17]. Thus, predicting BOS could allow
for early intervention, potentially preventing irreversible
lung damage and improving outcomes.
In this study, we proposed that through serial pulmonary
function testing after HSCT, detection of early spirometric
changes could identify patients at risk for BOS. Before this
study, evidence for this strategy was lacking. Accordingly,
less than half of the transplant centers perform regular PFT
screening for BOS [18]. At our institution, we performed
routine spirometry every 3months during the ﬁrst year post-
transplant and every 3 to 6 months beyond 1 year post-
transplant. We retrospectively reviewed all spirometry data
to identify BOS 0p, deﬁned as a decrease in the percent-
predicted FEV1 of 10% or a decrease in the percent-
predicted FEF25-75 of 25% and not meeting criteria for
BOS, similar to BOS stage 0p in lung transplantation patients
[5]. To ensure these changes were not transient, we only
identiﬁed patients as meeting BOS 0p if they had a second
PFT performed that demonstrated a persistent decline in
lung function.
Based on our data, we conclude that BOS 0p may be a
suitable method to identify patients at risk for BOS. Patients
who met criteria for BOS 0p were signiﬁcantly more likely to
develop BOS (HR, 3.22; P < .001). Further, the sensitivity for
the detection of BOS by the BOS 0p criteria was good (85%),
and a negative result within 2 years indicates that BOS is
unlikely (negative predictive value¼ 98%). Finally, criteria for
BOS 0p were met at a median of 222 days (range, 21 to 1039)
before detection of BOS.
Patients with chronic GVHD were at an overwhelmingly
higher risk for BOS 0p (HR, 23; P < .001). Further, patients
with a history of lung disease (chronic obstructive pulmo-
nary disease, asthma, pulmonary embolism) pretransplant
were at a higher risk for BOS 0p (HR, 2.48; P ¼ .001). These
patients may warrant closer screening for BOS 0p compared
with other patients post-transplant.
The operating characteristics of BOS 0p in allogeneic
HSCT patients were similar to the results reported in the
lung transplantation population [6,7]. In allogeneic HSCT
patients, BOS 0p criteria operated with good sensitivity
(85%) and speciﬁcity (78%), which is consistent with the
operating characteristics reported for BOS stage 0p within a
retrospective cohort study of double-lung transplantation
patients (sensitivity ¼ 79%, speciﬁcity ¼ 80%) [6]. There was
a difference in our patient population: We found a lower
positive predictive value (29%) compared with the positive
predictive value of BOS stage 0p in lung transplantation
patients (77%). The higher false-positive rate leading to this
result in our patient population can likely be attributed to
the lower prevalence of BOS (5%) after allogeneic HSCT
compared with the higher prevalence of BOS after lung
transplantation (50%) [6]. The trade-off to achieve a lower
false-positive rate in our population would likely be lower
sensitivity, which is undesirable given the high morbidity
associated with BOS.
There are several potential limitations to this study. First,
the small number of patients who developed BOS 0p and
BOS limited our ability to assess baseline characteristics as
risk factors for either BOS 0p or BOS. Second, there was the
lack of standardization in screening methods after 1 year,
potentially introducing bias. Although most patients un-
derwent spirometry every 3 months between years 1 and 2,
several underwent spirometry every 6 months, especially if
they appeared to be healthy and if they did not have chronic
GVHD. Increased screening in patients with chronic GVHD
may partially contribute to the increased detection of BOS
0p compared with patients without chronic GVHD. Third,
variability in screening interval between 1 and 2 years may
have biased the reported operating characteristics for BOS
0p. We attempted to minimize bias in our reported sensi-
tivity and negative predictive value by only evaluating pa-
tients who underwent a minimum of 3 PFTs and by only
looking at spirometry data up to 2 years to detect BOS 0p. A
minimum of 3 PFTs were necessary to detect BOS 0p ac-
cording to the methods we used. Limiting our detection
period to 2 years ensured all patients were screened over a
uniform period of time for BOS 0p. However, BOS 0p
conceivably could have been under-reported in individuals
screened less frequently. Fourth, because BOS 0p was mostly
detected in patients with either active acute or chronic
GVHD, the use of immunosuppression for GVHD at other
Table 3
Associations with BOS 0p
Risk Factor HR P
Age .99 .13
Sex
Male 1.00 (ref) .43
Female .84
Stem cell source
Bone marrow 1.00 (ref) .61
Peripheral blood 1.25
Myeloablative, busulfan 1.27 .30
TBI 1.06 .84
Previous tobacco use 1.04 .86
Previous lung disease 2.29 .004
Grades III-IV acute GVHD 1.85 .03
Chronic GHVD 22.8 <.001
Table 4
Predictive Measurements for BOS 0p
Criterion Sensitivity Speciﬁcity PPV NPV
FEV1 0p 77% 81% 30% 97%
FEF25-75 0p 65% 88% 37% 96%
FEV1 or FEF25-75 0p (BOS 0p) 85% 78% 29% 98%
PPV indicates positive predictive value; NPV, negative predictive value.
Predictive measurements of BOS 0p by FEV1 criterion, FEF25-75 criterion, or
FEV1 or FEF25-75 criterion.
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sites may have affected the time from detection of BOS 0p to
BOS.
Future studies designed to actively detect BOS 0p and BOS
are essential to conﬁrm and build on our ﬁndings. A pro-
spective study with deﬁned screening intervals would
eliminate some of the bias encountered in this study and
provide a more accurate incidence of BOS 0p. Further, larger
patient cohorts need to be examined to help further deﬁne
risk factors for both BOS 0p and BOS. If these ﬁndings can be
conﬁrmed prospectively, patients found to develop BOS 0p
could be more closely monitored to identify additional risk
factors for BOS or studied in early intervention trials with the
goal to prevent or delay progression to BOS.
In summary, our ﬁndings provide evidence that through
routine spirometry, detection of BOS 0p within allogeneic
HSCT patientsmay adequately identify patients at risk for the
development of BOS. Our ﬁndings also suggest screening for
BOS 0p should particularly be performed in patients with a
history of lung disease pretransplant and with chronic GVHD
at sites outside the lung. Upon further conﬁrmation of our
ﬁndings, detection of BOS 0p could ultimately identify pa-
tients whowould beneﬁt from early interventions to delay or
prevent progression to BOS.
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